General communications

19.10.2021

CureVac withdraws authorisation application for COVID-19 vaccine

Vaccine candidate CVnCoV no longer in rolling review procedure

15.10.2021

Reports of suspected adverse reactions to COVID-19 vaccines

8,757 reports of suspected adverse vaccination reactions (ADR) evaluated – the overall positive benefit-risk ratio of the vaccines remains

04.10.2021

New Head of Communication and media spokesperson at Swissmedic

Eliane Schmid has become Swissmedic’s new Head of Communication and media spokesperson.

28.09.2021

Vigilance for veterinary medicinal products: Adverse reactions reported in 2020

Report on adverse drug reactions (ADR) after use of veterinary medicinal products (VMP) in Switzerland

27.09.2021

Update – Warning about supposedly herbal products

Swissmedic is issuing an urgent warning regarding slimming products and other supposedly natural products

24.09.2021

Reports of suspected adverse reactions to COVID-19 vaccines

7,571 reports evaluated – the overall positive benefit-risk ratio of the vaccines remains

21.09.2021

Practical interpretation – Swiss authorised representative (CH-REP) for combination products

(Medicinal products with a medical device component)

16.09.2021

Swissmedic is reviewing the authorisation extension for a third dose of the COVID-19 vaccines from Pfizer/Biontech and Moderna

Pfizer Schweiz AG and Moderna Switzerland GmbH have submitted applications for a third vaccine dose (booster)

15.09.2021

Access Consortium: Alignment with ICMRA consensus on immunobridging for authorizing new COVID-19 vaccines

Access Consortium members agree that well-justified and appropriately designed immunobridging studies are an acceptable approach for authorizing COVID-19 vaccines.

07.09.2021

More than 1,600 participants at the information event on the new medical devices regulation

Successful Swissmedic online event on 2 September 2021

03.09.2021

Reports of suspected adverse reactions to COVID-19 vaccines

6,603 reports evaluated – the overall positive benefit-risk ratio of the vaccines remains

01.09.2021

Update to the forms New authorisation of human medicinal products HMV4 and Variations and authorisation extensions HMV4

Consent to exchange of information for applications in collaboration with Access Consortium and Project Orbis

13.08.2021

Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland – update

5,304 reports evaluated – the overall positive benefit-risk ratio of the vaccines remains

04.08.2021

Executive Summary - Benchmarking 2021

Comparison of Swiss approval times for human medicines with the EU and the USA

Last modification 19.04.2021

Top of page